BRPI0520078A2 - composição contendo quitosana para liberação sustentada de drogas - Google Patents

composição contendo quitosana para liberação sustentada de drogas

Info

Publication number
BRPI0520078A2
BRPI0520078A2 BRPI0520078-4A BRPI0520078A BRPI0520078A2 BR PI0520078 A2 BRPI0520078 A2 BR PI0520078A2 BR PI0520078 A BRPI0520078 A BR PI0520078A BR PI0520078 A2 BRPI0520078 A2 BR PI0520078A2
Authority
BR
Brazil
Prior art keywords
chitosan
drug release
sustained drug
containing composition
sustained
Prior art date
Application number
BRPI0520078-4A
Other languages
English (en)
Inventor
Adnan Badwan
Mayyas Mohammed Ahmad
Murshed Abdel-Qader Mohammed
Original Assignee
Jordanian Pharmaceutical Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jordanian Pharmaceutical Mfg filed Critical Jordanian Pharmaceutical Mfg
Publication of BRPI0520078A2 publication Critical patent/BRPI0520078A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIçãO CONTENDO QUITOSANA PARA LIBERAçãO SUSTENTADA DE DROGAS. A presente invenção refere-se a uma composição para liberação sustentada de drogas que compreende quitosana dissolvida em um solvente apresentando um pH abaixo de 4,0, onde a quitosana é selecionada do grupo de quitosanas que precipitam em uma faixa de pH de entre cerca de 3,0 e cerca de 7,5; e pelo menos um fármaco solúvel na solução de quitosana acima.
BRPI0520078-4A 2005-02-17 2005-12-19 composição contendo quitosana para liberação sustentada de drogas BRPI0520078A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05003405A EP1693051B1 (en) 2005-02-17 2005-02-17 Composition containing chitosan for sustained drug release
PCT/EP2005/013663 WO2006087028A1 (en) 2005-02-17 2005-12-19 Composition containing chitosan for sustained drug release

Publications (1)

Publication Number Publication Date
BRPI0520078A2 true BRPI0520078A2 (pt) 2009-04-14

Family

ID=34933799

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520078-4A BRPI0520078A2 (pt) 2005-02-17 2005-12-19 composição contendo quitosana para liberação sustentada de drogas

Country Status (16)

Country Link
US (1) US20100130612A1 (pt)
EP (2) EP1693051B1 (pt)
JP (1) JP2008530148A (pt)
KR (1) KR20070104643A (pt)
CN (1) CN101128183A (pt)
AP (1) AP2007004156A0 (pt)
AT (1) ATE397439T1 (pt)
AU (1) AU2005327852A1 (pt)
BR (1) BRPI0520078A2 (pt)
CA (1) CA2598364A1 (pt)
DE (1) DE602005007319D1 (pt)
EA (1) EA200701735A1 (pt)
MA (1) MA29317B1 (pt)
TN (1) TNSN07288A1 (pt)
WO (1) WO2006087028A1 (pt)
ZA (1) ZA200706807B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1955711A1 (en) * 2007-02-09 2008-08-13 The Jordanian Pharmaceutical Manufacturing Co. Composition comprising covalent conjugates of chitosan and an acidic drug for parenteral administration
EP1955693A1 (en) * 2007-02-09 2008-08-13 The Jordanian Pharmaceutical Manufacturing Co. Composition comprising chitosan and an acidic drug for oral controlled release
DE102009024542A1 (de) * 2009-06-10 2010-12-16 Arivine Pharma Ag Zusammensetzungen auf Basis von Chitosan-Oligosacchariden

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8608890A1 (es) * 1985-09-16 1986-09-01 Carulla Vekar S A Preparado farmaceutico liquido a base de teofilina de efec- tos retardados y procedimiento para su obtencion
JPH05339149A (ja) * 1992-02-27 1993-12-21 Taisho Pharmaceut Co Ltd 徐放性懸濁製剤
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
JP3605613B2 (ja) * 2001-10-01 2004-12-22 有限会社関西キトサン 植物栽培用液剤
GB0302738D0 (en) * 2003-02-06 2003-03-12 Advanced Biopolymers As Composition

Also Published As

Publication number Publication date
CA2598364A1 (en) 2006-08-24
TNSN07288A1 (en) 2008-12-31
CN101128183A (zh) 2008-02-20
AU2005327852A1 (en) 2006-08-24
EA200701735A1 (ru) 2008-02-28
EP1848397A1 (en) 2007-10-31
AP2007004156A0 (en) 2007-10-31
DE602005007319D1 (de) 2008-07-17
JP2008530148A (ja) 2008-08-07
KR20070104643A (ko) 2007-10-26
MA29317B1 (fr) 2008-03-03
US20100130612A1 (en) 2010-05-27
WO2006087028A1 (en) 2006-08-24
EP1693051A1 (en) 2006-08-23
ZA200706807B (en) 2008-10-29
ATE397439T1 (de) 2008-06-15
EP1693051B1 (en) 2008-06-04

Similar Documents

Publication Publication Date Title
BR0313723A (pt) Derivados de benzotiazol tendo atividade de agonista beta-2-adrenorreceptor
BRPI0720972B8 (pt) compostos análogos de ciclopamina e composições farmacêuticas compreendendo os referidos compostos
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
CL2008001839A1 (es) Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
CL2008000789A1 (es) Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras.
BRPI0514841A (pt) inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores
BRPI0611872B8 (pt) reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica
BRPI0514766A (pt) composições farmacêuticas
AR066877A1 (es) Suplementos dietarios para promover el crecimiento, la reparacion y el mantenimiento de huesos y articulaciones
UY29648A1 (es) Derivados de piridopirimidina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
BRPI0717156B8 (pt) inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende
BRPI0513278A (pt) uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton
HN2009000784A (es) Dihidropirazolonas sustituidas
ATE488232T1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
ECSP088288A (es) DERIVADOS DE 7-(2-AMINO-1-HIDROXI-ETIL)-4-HIDROXIBENZOTIAZOL-2(3H)-ONA COMO AGONISTAS DE LOS ADRENOCEPTORES ß2
DE602006017724D1 (de) Salicylsäurederivate
GT200400133AA (es) Derivados de pirrolo[3,4-c] pirazol, activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden. (solicitud fraccionaria no. 1, derivada de la patente no. pi-2004-0133).
BRPI0410238A (pt) compostos orgánicos
UY29510A1 (es) Derivados de urea, metodos para su fabricación, y usos de los mismos
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
BRPI0418330A (pt) composições sólidas de drogas de solubilidade baixa e poloxámeros
DK1885187T3 (da) Fremgangsmåde til behandling af lægemiddelresistent cancer
BRPI0615614A2 (pt) compostos orgánicos
GT200500338A (es) Nuevos inhibidores de hmg co-a reductasa basados en pirazol

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.